Brief: Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria
28/10/2024 07:42
Oct 28 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND
SECONDARY
ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2
STUDY IN CHRONIC INDUCIBLE URTICARIA
((Reuters.Briefs@thomsonreuters.com))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials